Serum levels of TNF-α, IL-1β, and hepcidin were reduced, while levels of IFN-γ and IL-2 in splenocyte supernatant were elevated, indicating anti-inflammation, iron metabolism regulation, and immune regulation of DGDSFE and DGDPE in MUPDDS, which led to a decrease in tumor incidence, tumor number, and tumor volume after 14 weeks of daily administration. Here, IL1B is linked to neoplasm.